Elranatamab: In the retrospective period, Each patient will be followed up until two years after the first dose of Elranatamab treatment, death, or withdrawal of consent, whichever occurs first. Information collection will be performed every month for the first 6 months after the first dose of Elranatamab treatment and then every 3 months for the following 18 months. The prospective period will include a Screening Period and a Treatment Period. Screening Period assessments will be performed within 7 days prior to treatment. During the Treatment Period, each patient will be followed up until two years after the first dose of Elranatamab treatment, death, or withdrawal of consent, whichever occurs first.
Study summary
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Participants with TCE-RRMM who have received or are planning to start Elranatamab treatment according to the local Health Authority approved product label (routine-care).
Patients must meet the following criteria to be eligible for inclusion in the study:
In the retrospective part:
1. Male or female patients above 18 years old
2. Patients diagnosed with RRMM(IMWG)
3. Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
4. Patients received at least 1 treatment dose of Elranatamab treatment after commercial launch in China and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
5. Patients understand and voluntarily sign an ICF .
In the prospective part:
1. Male or female patients above 18 years old
2. Patients diagnosed with RRMM (IMWG)
3. Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
4. Patients treated with elranatamab as monotherapy or a part of combination therapy and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
5. Patient understand and voluntarily sign an ICF. \*Note: If patients received Elranatamab treatment at a Hong Kong site,the treatment must consist the indications approved in Hong Kong.
Exclusion Criteria:
Patients meeting the following criteria will not be included in the study:
In the retrospective part:
1. Patients with documented diagnosis of other cancers prior to the diagnosis of MM
2. Patients enrolled in interventional clinical trials of any drug for MM treatment
3. Patients with incomplete medical records or missing clinical laboratory data that preclude effectiveness evaluation.
4. Patients who, in the opinion of the investigator, have other factors that make them unsuitable for study participation.
In the prospective part:
1. Patients with documented diagnosis of other cancers prior to the diagnosis of MM
2. Patients with contraindication listed in the package insert of elranatamab
3. Patients enrolled in interventional clinical trials of Elranatamab or any other drug for MM treatment
Primary outcome measure(s)
ORR — At the time from the date of first dose until the first documentation of PD, death or start of new anticancer therapy, whichever occurs first , assessed up to 27 months. Overall Response Rate (ORR):(including PR, VGPR, CR, and sCR)
Trial sites (1)
Facility
City
Region
Status
Peking University People's Hospital
Beijing
Beijing Municipality
More Peking University People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.